{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T12:13:09Z","timestamp":1792066389249,"version":"4.4.0"},"reference-count":50,"publisher":"The Japanese Society for Neuroendovascular Therapy","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["NOUSHINKEI KEKKANNAI TIRYOU","JNET"],"published-print":{"date-parts":[[2025]]},"DOI":"10.5797\/jnet.ra.2024-0102","type":"journal-article","created":{"date-parts":[[2025,5,26]],"date-time":"2025-05-26T22:09:52Z","timestamp":1748297392000},"page":"n\/a","source":"Crossref","is-referenced-by-count":5,"title":["Antithrombotic Therapy for Acute Coronary Syndrome"],"prefix":"10.5797","volume":"19","author":[{"given":"Toshiaki","family":"Toyota","sequence":"first","affiliation":[{"name":"Department of Cardiovascular Medicine, Kobe City Medical Center General Hospital, Kobe, Hyogo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirotoshi","family":"Watanabe","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Hirakata Kohsai Hospital, Hirakata, Osaka, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kitae","family":"Kim","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Kobe City Medical Center General Hospital, Kobe, Hyogo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yutaka","family":"Furukawa","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Kobe City Medical Center General Hospital, Kobe, Hyogo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takeshi","family":"Kimura","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Hirakata Kohsai Hospital, Hirakata, Osaka, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"3804","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1) Bergmark BA, Mathenge N, Merlini PA, et al. Acute coronary syndromes. <i>Lancet<\/i> 2022; 399: 1347\u20131358.","DOI":"10.1016\/S0140-6736(21)02391-6"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2) Fuster V, Badimon L, Badimon JJ, et al. The pathogenesis of coronary artery disease and the acute coronary syndromes (1). <i>N Engl J Med<\/i> 1992; 326: 242\u2013250.","DOI":"10.1056\/NEJM199201233260406"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3) Libby P, Ridker PM, Maseri A. Inflammation and atherosclerosis. <i>Circulation<\/i> 2002; 105: 1135\u20131143.","DOI":"10.1161\/hc0902.104353"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4) Niccoli G, Scalone G, Crea F. Acute myocardial infarction with no obstructive coronary atherosclerosis: mechanisms and management. <i>Eur Heart J<\/i> 2015; 36: 475\u2013481.","DOI":"10.1093\/eurheartj\/ehu469"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5) Calderone D, Capodanno D. Acute coronary syndrome with spontaneous coronary artery dissection: Which therapeutic option for a different pathophysiology? <i>Eur Heart J Suppl<\/i> 2020; 22: L33\u2013L37.","DOI":"10.1093\/eurheartj\/suaa130"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6) Beltrame JF. Assessing patients with myocardial infarction and nonobstructed coronary arteries (Minoca). <i>J Intern Med<\/i> 2013; 273: 182\u2013185.","DOI":"10.1111\/j.1365-2796.2012.02591.x"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7) Planer D, Mehran R, Ohman EM, et al. Prognosis of patients with non-ST-segment-elevation myocardial infarction and nonobstructive coronary artery disease: propensity-matched analysis from the Acute Catheterization and Urgent Intervention Triage Strategy trial. <i>Circ Cardiovasc Interv<\/i> 2014; 7: 285\u2013293.","DOI":"10.1161\/CIRCINTERVENTIONS.113.000606"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8) Boden WE, De Caterina R, Kaski JC, et al. Myocardial ischaemic syndromes: a new nomenclature to harmonize evolving international clinical practice guidelines. <i>Eur Heart J<\/i> 2024; 45: 3701\u20133706.","DOI":"10.1093\/eurheartj\/ehae278"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9) Franchi F, Angiolillo DJ. Novel antiplatelet agents in acute coronary syndrome. <i>Nat Rev Cardiol<\/i> 2015; 12: 30\u201347.","DOI":"10.1038\/nrcardio.2014.156"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10) Natsuaki M, Morimoto T, Yamaji K, et al. Prediction of thrombotic and bleeding events after percutaneous coronary intervention: CREDO-Kyoto thrombotic and bleeding risk scores. <i>J Am Heart Assoc<\/i> 2018; 7: e008708.","DOI":"10.1161\/JAHA.118.008708"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11) Urban P, Mehran R, Colleran R, et al. Defining high bleeding risk in patients undergoing percutaneous coronary intervention. <i>Circulation<\/i> 2019; 140: 240\u2013261.","DOI":"10.1161\/CIRCULATIONAHA.119.040167"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12) Natsuaki M, Morimoto T, Shiomi H, et al. Application of the academic research consortium high bleeding risk criteria in an all-comers registry of percutaneous coronary intervention. <i>Circ Cardiovasc Interv<\/i> 2019; 12: e008307.","DOI":"10.1161\/CIRCINTERVENTIONS.119.008307"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13) Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. <i>Lancet<\/i> 1988; 2: 349\u2013360.","DOI":"10.1016\/S0140-6736(88)92833-4"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14) Nakamura M, Kimura K, Kimura T, et al. JCS 2020 guideline focused update on antithrombotic therapy in patients with coronary artery disease. <i>Circ J<\/i> 2020; 84: 831\u2013865.","DOI":"10.1253\/circj.CJ-19-1109"},{"key":"15","unstructured":"15) Rao SV, O\u2019Donoghue ML, Ruel M, et al. 2025 ACC\/AHA\/ACEP\/NAEMSP\/SCAI Guideline for the Management of Patients With Acute Coronary Syndromes: A Report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines. <i>Circulation<\/i> 2025; 151: e771\u2013e862."},{"key":"16","doi-asserted-by":"crossref","unstructured":"16) Byrne RA, Rossello X, Coughlan JJ, et al. 2023 ESC guidelines for the management of acute coronary syndromes. <i>Eur Heart J<\/i> 2023; 44: 3720\u20133826.","DOI":"10.1093\/eurheartj\/ehad191"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17) Montalescot G, Zeymer U, Silvain J, et al. Intravenous enoxaparin or unfractionated heparin in primary percutaneous coronary intervention for ST-elevation myocardial infarction: the international randomised open-label ATOLL trial. <i>Lancet<\/i> 2011; 378: 693\u2013703.","DOI":"10.1016\/S0140-6736(11)60876-3"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18) Li Y, Liang Z, Qin L, et al. Bivalirudin plus a high-dose infusion versus heparin monotherapy in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention: a randomised trial. <i>Lancet<\/i> 2022; 400: 1847\u20131857.","DOI":"10.1016\/S0140-6736(22)01999-7"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19) Yusuf S, Mehta SR, Chrolavicius S, et al. Effects of fondaparinux on mortality and reinfarction in patients with acute ST-segment elevation myocardial infarction: the OASIS-6 randomized trial. <i>JAMA<\/i> 2006; 295: 1519\u20131530.","DOI":"10.1001\/jama.295.13.joc60038"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20) Leon MB, Baim DS, Popma JJ, et al. A clinical trial comparing three antithrombotic-drug regimens after coronary-artery stenting. Stent anticoagulation restenosis study investigators. <i>N Engl J Med<\/i> 1998; 339: 1665\u20131671.","DOI":"10.1056\/NEJM199812033392303"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21) McFadden EP, Stabile E, Regar E, et al. Late thrombosis in drug-eluting coronary stents after discontinuation of antiplatelet therapy. <i>Lancet<\/i> 2004; 364: 1519\u20131521.","DOI":"10.1016\/S0140-6736(04)17275-9"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22) R\u00e4ber L, Yamaji K, Kelb\u00e6k H, et al. Five-year clinical outcomes and intracoronary imaging findings of the COMFORTABLE AMI trial: randomized comparison of biodegradable polymer-based biolimus-eluting stents with bare-metal stents in patients with acute ST-segment elevation myocardial infarct. <i>Eur Heart J<\/i> 2019; 40: 1909\u20131919.","DOI":"10.1093\/eurheartj\/ehz074"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23) Sabat\u00e9 M, Brugaletta S, Cequier A, et al. Clinical outcomes in patients with ST-segment elevation myocardial infarction treated with everolimus-eluting stents versus bare-metal stents (EXAMINATION): 5-year results of a randomised trial. <i>Lancet<\/i> 2016; 387: 357\u2013366.","DOI":"10.1016\/S0140-6736(15)00548-6"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24) Toyota T, Shiomi H, Morimoto T, et al. Meta-analysis of long-term clinical outcomes of everolimus-eluting stents. <i>Am J Cardiol<\/i> 2015; 116: 187\u2013194.","DOI":"10.1016\/j.amjcard.2015.03.059"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25) Watanabe H, Morimoto T, Natsuaki M, et al. Comparison of clopidogrel monotherapy after 1 to 2 months of dual antiplatelet therapy with 12 months of dual antiplatelet therapy in patients with acute coronary syndrome: The STOPDAPT-2 ACS randomized clinical trial. <i>JAMA Cardiol<\/i> 2022; 7: 407\u2013417.","DOI":"10.1001\/jamacardio.2021.5244"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26) Watanabe H, Domei T, Morimoto T, et al. Details on the effect of very short dual antiplatelet therapy after drug-eluting stent implantation in patients with high bleeding risk: insight from the STOPDAPT-2 trial. <i>Cardiovasc Interv Ther<\/i> 2021; 36: 91\u2013103.","DOI":"10.1007\/s12928-020-00651-9"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27) Baber U, Dangas G, Angiolillo DJ, et al. Ticagrelor alone vs. ticagrelor plus aspirin following percutaneous coronary intervention in patients with non-ST-segment elevation acute coronary syndromes: TWILIGHT-ACS. <i>Eur Heart J<\/i> 2020; 41: 3533\u20133545.","DOI":"10.1093\/eurheartj\/ehaa670"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28) Kim BK, Hong SJ, Cho YH, et al. Effect of ticagrelor monotherapy vs ticagrelor with aspirin on major bleeding and cardiovascular events in patients with acute coronary syndrome: the TICO randomized clinical trial. <i>JAMA<\/i> 2020; 323: 2407\u20132416.","DOI":"10.1001\/jama.2020.7580"},{"key":"29","doi-asserted-by":"crossref","unstructured":"29) Shoji S, Kuno T, Fujisaki T, et al. De-escalation of dual antiplatelet therapy in patients with acute coronary syndromes. <i>J Am Coll Cardiol<\/i> 2021; 78: 763\u2013777.","DOI":"10.1016\/j.jacc.2021.06.012"},{"key":"30","doi-asserted-by":"crossref","unstructured":"30) Kang J, Rizas KD, Park KW, et al. Dual antiplatelet therapy de-escalation in acute coronary syndrome: an individual patient meta-analysis. <i>Eur Heart J<\/i> 2023; 44: 1360\u20131370.","DOI":"10.1093\/eurheartj\/ehac829"},{"key":"31","doi-asserted-by":"crossref","unstructured":"31) Dewilde WJ, Oirbans T, Verheugt FW, et al. Use of clopidogrel with or without aspirin in patients taking oral anticoagulant therapy and undergoing percutaneous coronary intervention: an open-label, randomised, controlled trial. <i>Lancet<\/i> 2013; 381: 1107\u20131115.","DOI":"10.1016\/S0140-6736(12)62177-1"},{"key":"32","doi-asserted-by":"crossref","unstructured":"32) Gibson CM, Mehran R, Bode C, et al. Prevention of bleeding in patients with atrial fibrillation undergoing PCI. <i>N Engl J Med<\/i> 2016; 375: 2423\u20132434.","DOI":"10.1056\/NEJMoa1611594"},{"key":"33","doi-asserted-by":"crossref","unstructured":"33) Cannon CP, Bhatt DL, Oldgren J, et al. Dual antithrombotic therapy with dabigatran after PCI in atrial fibrillation. <i>N Engl J Med<\/i> 2017; 377: 1513\u20131524.","DOI":"10.1056\/NEJMoa1708454"},{"key":"34","doi-asserted-by":"crossref","unstructured":"34) Lopes RD, Heizer G, Aronson R, et al. Antithrombotic therapy after acute coronary syndrome or PCI in atrial fibrillation. <i>N Engl J Med<\/i> 2019; 380: 1509\u20131524.","DOI":"10.1056\/NEJMoa1817083"},{"key":"35","doi-asserted-by":"crossref","unstructured":"35) Vranckx P, Valgimigli M, Eckardt L, et al. Edoxaban-based versus vitamin K antagonist-based antithrombotic regimen after successful coronary stenting in patients with atrial fibrillation (ENTRUST-AF PCI): a randomised, open-label, phase 3b trial. <i>Lancet<\/i> 2019; 394: 1335\u20131343.","DOI":"10.1016\/S0140-6736(19)31872-0"},{"key":"36","doi-asserted-by":"crossref","unstructured":"36) Vos NS, Fagel ND, Amoroso G, et al. Paclitaxel-coated balloon angioplasty versus drug-eluting stent in acute myocardial infarction: the revelation randomized trial. <i>JACC Cardiovasc Interv<\/i> 2019; 12: 1691\u20131699.","DOI":"10.1016\/j.jcin.2019.04.016"},{"key":"37","doi-asserted-by":"crossref","unstructured":"37) Scheller B, Ohlow MA, Ewen S, et al. Bare metal or drug-eluting stent versus drug-coated balloon in non-ST-elevation myocardial infarction: the randomised PEPCAD NSTEMI trial. <i>EuroIntervention<\/i> 2020; 15: 1527\u20131533.","DOI":"10.4244\/EIJ-D-19-00723"},{"key":"38","doi-asserted-by":"crossref","unstructured":"38) Gao C, He X, Ouyang F, et al. Drug-coated balloon angioplasty with rescue stenting versus intended stenting for the treatment of patients with de novo coronary artery lesions (REC-CAGEFREE I): an open-label, randomised, non-inferiority trial. <i>Lancet<\/i> 2024; 404: 1040\u20131050.","DOI":"10.1016\/S0140-6736(24)01594-0"},{"key":"39","doi-asserted-by":"crossref","unstructured":"39) Zhu Y, Zhang W, Dimagli A, et al. Antiplatelet therapy after coronary artery bypass surgery: five year follow-up of randomised dacab trial. <i>BMJ<\/i> 2024; 385: e075707.","DOI":"10.1136\/bmj-2023-075707"},{"key":"40","doi-asserted-by":"crossref","unstructured":"40) Lindholm D, Varenhorst C, Cannon CP, et al. Ticagrelor vs. clopidogrel in patients with non-ST-elevation acute coronary syndrome with or without revascularization: results from the PLATO trial. <i>Eur Heart J<\/i> 2014; 35: 2083\u20132093.","DOI":"10.1093\/eurheartj\/ehu160"},{"key":"41","doi-asserted-by":"crossref","unstructured":"41) Lindahl B, Baron T, Erlinge D, et al. Medical therapy for secondary prevention and long-term outcome in patients with myocardial infarction with nonobstructive coronary artery disease. <i>Circulation<\/i> 2017; 135: 1481\u20131489.","DOI":"10.1161\/CIRCULATIONAHA.116.026336"},{"key":"42","doi-asserted-by":"crossref","unstructured":"42) Bossard M, Gao P, Boden W, et al. Antiplatelet therapy in patients with myocardial infarction without obstructive coronary artery disease. <i>Heart<\/i> 2021; 107: 1739\u20131747.","DOI":"10.1136\/heartjnl-2020-318045"},{"key":"43","doi-asserted-by":"crossref","unstructured":"43) Kovach CP, Hebbe A, O\u2019Donnell CI, et al. Comparison of patients with nonobstructive coronary artery disease with versus without myocardial infarction (from the VA clinical assessment reporting and tracking [CART] program). <i>Am J Cardiol<\/i> 2021; 146: 1\u20137.","DOI":"10.1016\/j.amjcard.2021.01.015"},{"key":"44","doi-asserted-by":"crossref","unstructured":"44) Sibbing D, Aradi D, Alexopoulos D, et al. Updated expert consensus statement on platelet function and genetic testing for guiding P2Y<sub>12<\/sub> receptor inhibitor treatment in percutaneous coronary intervention. <i>JACC Cardiovasc Interv<\/i> 2019; 12: 1521\u20131537.","DOI":"10.1016\/j.jcin.2019.03.034"},{"key":"45","doi-asserted-by":"crossref","unstructured":"45) Pereira NL, Farkouh ME, So D, et al. Effect of genotype-guided oral P2y12 inhibitor selection vs conventional clopidogrel therapy on ischemic outcomes after percutaneous coronary intervention: the TAILOR-PCI randomized clinical trial. <i>JAMA<\/i> 2020; 324: 761\u2013771.","DOI":"10.1001\/jama.2020.12443"},{"key":"46","doi-asserted-by":"crossref","unstructured":"46) Natsuaki M, Watanabe H, Morimoto T, et al. An aspirin-free versus dual antiplatelet strategy for coronary stenting: STOPDAPT-3 randomized trial. <i>Circulation<\/i> 2024; 149: 585\u2013600.","DOI":"10.1161\/CIRCULATIONAHA.123.066720"},{"key":"47","doi-asserted-by":"crossref","unstructured":"47) Hess CN, James S, Lopes RD, et al. Apixaban plus mono versus dual antiplatelet therapy in acute coronary syndromes: insights from the APPRAISE-2 trial. <i>J Am Coll Cardiol<\/i> 2015; 66: 777\u2013787.","DOI":"10.1016\/j.jacc.2015.06.027"},{"key":"48","doi-asserted-by":"crossref","unstructured":"48) Mega JL, Braunwald E, Wiviott SD, et al. Rivaroxaban in patients with a recent acute coronary syndrome. <i>N Engl J Med<\/i> 2012; 366: 9\u201319.","DOI":"10.1056\/NEJMoa1112277"},{"key":"49","doi-asserted-by":"crossref","unstructured":"49) Toyota T, Morimoto T, Shiomi H, et al. Very late scaffold thrombosis of bioresorbable vascular scaffold: systematic review and a meta-analysis. <i>JACC Cardiovasc Interv<\/i> 2017; 10: 27\u201337.","DOI":"10.1016\/j.jcin.2016.10.027"},{"key":"50","doi-asserted-by":"crossref","unstructured":"50) Jinnouchi H, Torii S, Sakamoto A, et al. Fully bioresorbable vascular scaffolds: lessons learned and future directions. <i>Nat Rev Cardiol<\/i> 2019; 16: 286\u2013304.","DOI":"10.1038\/s41569-018-0124-7"}],"container-title":["Journal of Neuroendovascular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jnet\/19\/1\/19_ra.2024-0102\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,31]],"date-time":"2025-05-31T04:12:20Z","timestamp":1748664740000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jnet\/19\/1\/19_ra.2024-0102\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025]]},"references-count":50,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.5797\/jnet.ra.2024-0102","relation":{},"ISSN":["1882-4072","2186-2494"],"issn-type":[{"value":"1882-4072","type":"print"},{"value":"2186-2494","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025]]},"article-number":"ra.2024-0102"}}